The knockdown of CoREST2 in an in situ xenograft mouse model resulted in reduced primary tumor growth and lung metastasis, suggesting that disruption of the interaction between KDM1A, CoREST2, and STAT3 serves as a therapeutic strategy to target neuroendocrine differentiation [101]. The gene discussed is KDM1A; the disease is neoplasm.